NCT02452242 - Safety, PK and PD Study of ABX464 in Untreated HIV Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

May 31, 2016

Conditions

Human Immunodeficiency Virus Infections

Interventions

DRUG

ABX464

25, 50, 75, 100, 150 mg, i.e. 1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks

OTHER

Placebo

1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks

Trial Locations (4)

HIV-NAT, Thai Red Cross AIDS Research Center, Bangkok

Siriraj Hospital, Mahidol University, Bangkok

Chiang Mai University, Chiang Mai

CAP Research Ltd, Curepipe